Accessibility Menu

Gilead Sciences(FRA) GIS

Market Cap€158.86BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)+1,273%
5 Year+108%
1 Year+31%
1 Month+11%
€125.88
-1.75%
-2.24Today
Gilead Sciences last closing stock price
MetricPriceDate
Last closeEUR 125.902026-08-31
Gilead Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.82%EUR 124.882026-08-24
1 month+11.36%EUR 113.062026-07-31
3 month+14.14%EUR 110.302026-06-02
Year to date+18.46%EUR 106.282025-12-30
1 year+30.82%EUR 96.242025-08-29
3 year+77.32%EUR 71.002023-09-01
5 year+108.37%EUR 60.422021-09-01
Since inception+1,272.82%EUR 9.332010-08-05

Gilead Sciences Financials at a Glance

Market Cap

€158.86BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€26.19K

Net Income (TTM)

-€2.81K

EPS (TTM)

-€2.31

P/E Ratio

-55.57

Dividend

€2.77

Beta (Volatility)

-0.01 (Low)

Price

€125.88

Volume

50

Open

€125.30

Previous Close

€125.88

Daily Range

€125.30 - €125.88

52-Week Range

€93.42 - €132.00

Estimated Earnings Date

N/A

GIS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Industry

Biotechnology

Employees

17,000

CEO

Daniel P. O'Day, MBA

GIS Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-20.75%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-1.80%

Dividend Yield

2.16%

Payout Ratio

N/A

Stock Overview

Market Cap

€158.86BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.24B

Volume

50

Avg. Volume

362.242

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Gilead Sciences Performance Analysis

Gilead Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 25,771,324,35311.3%
20232023-12-31EUR 25,027,850,792-2.9%
20242024-12-31EUR 26,557,497,9106.1%
20252025-12-31EUR 26,093,013,765-1.7%
Gilead Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 3.46-17.0%
20232023-12-31EUR 4.1720.3%
20242024-12-31EUR 0.35-91.5%
20252025-12-31EUR 6.011599.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€6.73K

+1.1%

Gross Profit

€5.37K

+1.1%

Gross Margin

79.81%

+1.0%

Market Cap

€158.86BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€8.10

N/A

Employees

17,000

N/A

Net Income

-€9.03K

-5.2%

EBITDA

€2.88K

+0.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€25.74K

+0.4%

Total Debt

€22.96K

+1.1%

Accounts Receivable

€4.42K

+1.1%

Inventory

€1.71K

+1.1%

Long Term Debt

€20.84K

+1.1%

Short Term Debt

€2.11K

+0.9%

Return on Assets

-6.21%

-0.5%

Return on Invested Capital

11.27%

+1.5%

Free Cash Flow

€2.97K

+5.7%

Operating Cash Flow

€3.09K

+5.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About GIS

What is the current price of Gilead Sciences?

Gilead Sciences is trading at €125.88 per share.

What is the 52-week range for Gilead Sciences?

Over the past 52 weeks, Gilead Sciences has traded between €93.42 and €132.00.

How much debt does Gilead Sciences have?

As of the most recent reporting period, Gilead Sciences reported total debt of €22.96B.

How much cash does Gilead Sciences have on hand?

Gilead Sciences reported €2.78B in cash and cash equivalents in its most recent financial results.

What is Gilead Sciences’s dividend yield?

Gilead Sciences currently has a dividend yield of 2.16%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.